Why Contraceptive Innovation?

Despite the availability of various contraceptive methods, more than 200 million women in developing countries want to avoid or delay pregnancy yet are not using an effective family planning method. For some of these women, access to contraception is limited. For others, currently available methods do not meet their needs or preferences or are unaffordable. Innovative solutions are needed in the areas of product development, registration, pricing, and introduction to address these barriers.

Join the exchange and become part of the solution!

Visit our resource library for additional information about the need for contraceptive innovation.


A one-stop shop for resources related to contraceptive research and development

The CTI Exchange offers resources about contraceptive research and development, including information about products currently in development, preclinical and clinical research, and opportunities for future investment. This easily searchable resource library also includes information about regulatory requirements, quality assurance standards, intellectual property, and product introduction strategies, as well as tools for advocacy.

View all resources


Latest news, events, resources, and thought pieces from the Exchange's blog


International Conference on Family Planning
The fifth International Conference on Family Planning (ICFP) was held in November in Kigali, Rwanda. Contraceptive technology innovation was highlighted throughout the week.

Launch of first clinical trial for male contraceptive gel
Three sites in the U.S. started enrolling couples in the first-ever clinical trial to test the safety and efficacy of a gel for men to prevent unintended pregnancy.

Celebrating #NextGenContraception on World Contraception Day
The CTI Exchange joins global partners in celebrating World Contraception Day. To celebrate, we are pleased to share highlights from our recent #NextGenContraception campaign.

FDA approvals for Annovera and Natural Cycles app
On August 10, 2018, the U.S. Food and Drug Administration made two major announcements related to contraception. The FDA permitted marketing of Natural Cycles and it approved AnnoveraTM.

Newly Published: Can WIN 18,446 function as a nonhormonal fema...
Vitamin A deficient women produce less retinoic acid, and this deficiency reduces their fertility. Meanwhile, the compound WIN 18,446 inhibits retinoic acid production. WIN 18,446 has a...

A Summer in Contraceptive Development
This summer, we got to work in CTI as undergraduate interns. We knew we were going to be working in contraceptive research and development (R&D), but there were far fewer lab coats and chemi...

New Summer Twitter Campaign: #NextGenContraception
The CTI Exchange’s summer social media campaign aims to highlight the importance of new contraceptive research and development to meet the needs and preferences of women and men globally. ...

Report on the International Family Planning Landscape
The Center for Global Development (CGD) and Kaiser Family Foundation (KFF) held an international family planning leadership retreat to discuss the current landscape of the field.

Newly Published Results of a Phase I/II Trial for LNG-only Patche...
A recently published article reports on a phase I/II pharmacokinetic and pharmacodynamic clinical trial of two levonorgestrel (LNG)-only contraceptive patches.

Published Review on Responses to Contraceptive-Induced Menstrual ...
A recently published review in Reproductive Health summarizes research on women’s responses to contraceptive-induced menstrual bleeding changes (CIMBCs).

Vaginal Ring Dose-Finding Results Published
Results from a dose-finding study on a novel vaginal ring utilizing 17β-estradiol rather than ethinyl estradiol were published in the May issue of Contraception.

Upcoming Webinar Series: “Mind the Gap”
The Reproductive Health Supplies Coalition is hosting a webinar series, titled “Mind the Gap”, on their latest Global Contraceptive Commodity Gap Analysis (CGA 2018).

Featured Resources

Other key resources related to contraceptive research and development

Calliope, the Contraceptive Pipeline Database, includes information on potential contraceptive targets and leads, products in pre-clinical and clinical development, and a selection of novel and long-acting products with limited market availability.
CAPRI, the Contraceptive Active Pharmaceutical Ingredient Database, lists biological and chemical properties for 27 active pharmaceutical ingredients found in contraceptives, along with data on their pharmacology, toxicology, impurities, metabolites, and use in marketed products.
Contraceptive Drug Interactions is a database that catalogues potential interactions between contraceptive drugs and drugs from other therapeutic classes. Changes in drug pharmacokinetics, effectiveness, and adverse effects are provided.


We want you to join the exchange!

The CTI Exchange looks to partners to help generate and share resources. Contact us with your ideas, materials, or questions, or sign up to receive more information. We also encourage you to provide your feedback